Skip to contentC
Cerenome, Inc.
C
CNSYCerenome, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.41M$1.41Mderivedno prior Q4 2023 on file Net Income-$3.90M-$3.90MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cerenome, Inc. · CIK 1095981 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$3,900,000N/M Operating Cash Flowderived-$1,211,000N/M Free Cash Flowderived-$1,222,000N/M Margins · derivedOperating margin-276.2%
Net margin-276.4%
ended Dec 31, 2024 · filed Mar 31, 2025 · 90 d after period end